Trial Profile

A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants With Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 01 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary) ; Relatlimab (Primary)
Indications Anaplastic large cell lymphoma; B-cell lymphoma; Diffuse large B cell lymphoma; Hodgkin's disease; Non-Hodgkin's lymphoma
Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
Acronyms RELATIVITY-069
Sponsors Bristol-Myers Squibb

21 Feb 2023 Planned primary completion date changed from 19 Nov 2026 to 5 Jul 2028.
11 Jan 2023 Planned End Date changed from 31 May 2027 to 5 Jul 2028.
11 Jan 2023 Planned primary completion date changed from 31 May 2027 to 19 Nov 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com